Skip to main content

Table 1 Comparisons of sex, age, H. pylori infection, and mutations of the 23S rRNA gene between subjects with and without CLR use history

From: Prevalence of A2143G mutation of H. pylori-23S rRNA in Chinese subjects with and without clarithromycin use history

Groups   Placebo OA OAC (Total)
CLR use history   - - +  
Case No.   310 307 153 770
Sex ratio (M:F)   1:1.00 1:1.13 1:0.82 1:1.01
Age (yrs) (Mean ± SD)   45.3 ± 8.4 45.0 ± 8.4 45.7 ± 8.6 45.2 ± 8.5
H. pylori-positive rate in 2003 (%) 13C-UBT 90.6 (280/309) 54.11 (166/307) 53.3 (81/152) 68.1 (527/768)
  ELISA 92.5 (283/306) 62.11 (185/298) 44.12 (64/145) 71.0 (532/749)
  23S rRNA 83.9 (260/310) 51.11 (157/307) 26.82 (41/153) 59.5 (458/770)
Proportion of 2143G-positive H. pylori (%) Total CLRr 13.8 (36/260) 10.2 (16/157) 31.73 (13/41) 14.2 (65/458)
  CLRr & s 9.6 (25/260) 6.4 (10/157) 14.6 (6/41) 9.0 (41/458)
Proportion of MboII-RFLP-positive H. pylori (%) 2222CTTCA 0.4 (1/260) 1.9 (3/157) 4.94 (2/41) 1.3 (6/458)
  2081GAAG 1.9 (5/260) 1.3 (2/157) 14.65 (4/41) 2.4 (11/458)
  1. 1: OA group vs. placebo group, p < 0.0000;
  2. 2: OAC group vs. OA group, p < 0.0005;
  3. 3: OAC group vs. OA group, OR = 4.09, 95%CI [1.64–10.23]; OAC group vs. placebo group, OR = 2.89, 95%CI [1.28–6.46];
  4. 4: OAC group vs. OA group, OR = 2.63, 95%CI [0.30–20.29]; OAC group vs. placebo group, OR = 13.28, 95%CI [0.91–379];
  5. 5: OAC group vs. OA group, OR = 8.38, 95%CI [1.25–68.84]; OAC group vs. placebo group, OR = 5.51, 95%CI [1.18–25.12]